Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2023-2024
Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 24, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of May 21, 2024: 13 items on BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 24, 2024: 11 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth McKee Anderson | 143,725,729 | -- | -- | 9,003,309 | 10,260,612 | 94% | Elected | — |
| Elect Director: Barbara W. Bodem | 152,126,450 | -- | -- | 602,588 | 10,260,612 | 99.6% | Elected | — |
| Elect Director: Athena Countouriotis, M.D. | 152,107,502 | -- | -- | 621,536 | 10,260,612 | 99.5% | Elected | — |
| Elect Director: Willard Dere, M.D. | 147,153,181 | -- | -- | 5,575,857 | 10,260,612 | 96% | Elected | — |
| Elect Director: Mark J. Enyedy | 152,125,947 | -- | -- | 603,091 | 10,260,612 | 99.6% | Elected | — |
| Elect Director: Alexander Hardy | 151,780,693 | -- | -- | 948,345 | 10,260,612 | 99.3% | Elected | — |
| Elect Director: Elaine J. Heron, Ph.D. | 144,192,766 | -- | -- | 8,536,272 | 10,260,612 | 94% | Elected | — |
| Elect Director: Maykin Ho, Ph.D. | 143,813,807 | -- | -- | 8,915,231 | 10,260,612 | 94% | Elected | — |
| Elect Director: Robert J. Hombach | 149,094,947 | -- | -- | 3,634,091 | 10,260,612 | 98% | Elected | — |
| Elect Director: Richard A. Meier | 146,622,137 | -- | -- | 6,106,901 | 10,260,612 | 96% | Elected | — |
| Elect Director: David E.I. Pyott, M.D. (Hon.) | 146,332,496 | -- | -- | 6,396,542 | 10,260,612 | 96% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2024, as set forth in the Proxy | 156,548,552 | 6,404,458 | 36,640 | -- | -- | 96% | Approved | — |
| 3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes | 141,887,490 | 10,757,670 | 83,878 | -- | 10,260,612 | 93% | Approved | — |
Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 24, 2024 — read the filing on EDGAR.
Each item below shows how the 567 asset managers that disclosed a BIOMARIN PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Athena Countouriotis
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis, M.D.”): 152,107,502 for, 621,536 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,933,419 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Alexander Hardy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 151,780,693 for, 948,345 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,931,049 for, 640 withheld, 14,575 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Barbara W. Bodem
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 152,126,450 for, 602,588 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,933,419 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David E.I. Pyott
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: David E.I. Pyott, M.D. (Hon.)”): 146,332,496 for, 6,396,542 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,905,893 for, 21,053 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elizabeth M. Anderson
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth McKee Anderson”): 143,725,729 for, 9,003,309 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,905,893 for, 21,053 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elaine J. Heron
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elaine J. Heron, Ph.D.”): 144,192,766 for, 8,536,272 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 78,663,460 for, 1,245,985 withheld, 36,819 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,184 | 0 | 0 | 374 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 342,551 | Withhold |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Mark J. Enyedy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 152,125,947 for, 603,091 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,933,419 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Maykin Ho
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho, Ph.D.”): 143,813,807 for, 8,915,231 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 76,789,899 for, 2,861,210 withheld, 295,155 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,883,747 | 0 | 0 | 89,167 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 0 | 110 | For |
| Charles Schwab | 0 | 0 | 0 | 1,328,936 | Withhold |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Richard A. Meier
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 146,622,137 for, 6,106,901 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,548,726 for, 385,333 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,412 | 0 | 0 | 146 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 342,551 | Withhold |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert J. Hombach
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 149,094,947 for, 3,634,091 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,925,556 for, 1,390 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 0 | 110 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Willard Dere
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere, M.D.”): 147,153,181 for, 5,575,857 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 127 asset managers below reported 79,040,610 for, 893,414 withheld, 12,240 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 19 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 141,887,490 for, 10,757,670 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,180,169 | 9,524 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,551 | 0 | 0 | Against |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Fund voting reports, all 129 managers: 79,415,775 for, 593,129 against, 1,973 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 17,933,372 | 0 | 0 | 0 | For |
| Dodge & Cox | 13,181,239 | 0 | 0 | 0 | For |
| BlackRock | 6,853,356 | 387 | 0 | 0 | For |
| Capital Research Global Investors | 6,517,745 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,416,288 | 0 | 0 | 0 | For |
| State Street | 6,069,369 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,985,409 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,233,162 | 0 | 0 | 0 | For |
| JPMorgan | 1,827,547 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 1,650,301 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,587,644 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 1,500,749 | 0 | 0 | 0 | For |
| Citadel | 1,464,076 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,021 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,224,356 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,181,459 | 0 | 0 | 0 | For |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 0 | 1,113,212 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 1,083,500 | 0 | 0 | 0 | For |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 1,052,717 | 0 | 0 | 0 | For |
| Northern Trust | 1,019,583 | 9,005 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 885,390 | 0 | 0 | Against |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| DnB Asset Management AS | 850,667 | 0 | 0 | 0 | For |
| Nuveen | 827,207 | 0 | 0 | 0 | For |
| Manning & Napier | 0 | 816,140 | 0 | 0 | Against |
Institutional-manager reports, all 469 managers: 99,487,767 for, 7,558,115 against, 95,532 abstained, 634 not voted, 1 unknown. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 156,548,552 for, 6,404,458 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2024.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 133 asset managers below reported 79,572,737 for, 443,871 against, 1,992 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,414 | 144 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,551 | 0 | 0 | Against |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. See all 133 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,776,577 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 16.32% |
| 2 | Dodge & Cox | 5.56% |
| 3 | BlackRock | 3.16% |
| 4 | AMCAP FUND | 2.59% |
| 5 | PRIMECAP Odyssey Funds | 1.90% |
| 6 | Columbia Threadneedle | 1.69% |
| 7 | Fidelity | 1.67% |
| 8 | State Street | 1.29% |
| 9 | Charles Schwab | 0.70% |
| 10 | Capital Group | 0.69% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP MANAGEMENT CO/CA/ | 9.45% |
| 2 | Dodge & Cox | 6.95% |
| 3 | BlackRock | 3.61% |
| 4 | Capital Research Global Investors | 3.43% |
| 5 | VIKING GLOBAL INVESTORS LP | 3.38% |
| 6 | State Street | 3.20% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.57% |
| 8 | Avoro Capital Advisors LLC | 1.18% |
| 9 | JPMorgan | 0.96% |
| 10 | Newton Investment Management North America, LLC | 0.87% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 9.79% | 13F |
| PRIMECAP Management Company | 9.70% | DEF14A |
| BlackRock, Inc. | 7.77% | DEF14A |
| Dodge & Cox | 7.37% | DEF14A |
| S.S. OR | 7.37% | 13G |
| Capital Research Global Investors | 5.68% | DEF14A |
| State Street | 3.63% | 13F |
| Norges Bank | 1.52% | 13F |
| Millennium Management | 1.39% | 13F |
| BNY Mellon | 1.39% | 13F |
Percentages above are of 189,776,577 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held May 21, 2024, in the 2023-2024 proxy season, 567 asset managers reported how they voted on 13 ballot items in their SEC Form N-PX filings, covering 6,861 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BIOMARIN PHARMACEUTICAL INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 24, 2024.
BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.